Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma

British Journal of Cancer

Volumn 110, Issue 7, 2014, Pages 1778-1784

  Saroufim, A ^a   Messai, Y ^a   Hasmim, M ^a   Rioux, N ^b   Iacovelli, R ^a   Verhoest, G ^b   Bensalah, K ^b   Patard, J J ^a,c   Albiges, L ^a   Azzarone, B ^d   Escudier, B ^a   Chouaib, S ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c Kremlin Bicêtre Hospital   (France)

^d G GASLINI INSTITUTE   (Italy)

Author keywords

ccRCC; CD105; endothelial; prognosis; tumoral

Indexed keywords

ENDOGLIN;

ADULT; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER STEM CELL; CAPILLARY DENSITY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY VEIN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; AGED; ANTIGEN EXPRESSION; CANCER SURVIVAL; PREDICTOR VARIABLE; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; VASCULAR ENDOTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84897576123     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.71     Document Type: Article

References (29)

1. Albiges L, Salem M, Rini B, Escudier B (2011) Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematol Oncol Clin North Am 25(4): 813-833.
2. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW (1995) Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 87(21): 1603-1612.
3. Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G (2008) Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J 22(10): 3696-3705.
4. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353(23): 2477-2490.
5. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, Ellis LM (2008) Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 14(7): 1931-1937.
6. Delahunt B, Bethwaite PB, Thornton A (1997) Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br J Urol 80(3): 401-404.
7. Derynck R, Feng XH (1997) TGF-beta receptor signaling. Biochim Biophys Acta 1333(2): F105-F150.
8. Dubinski W, Gabril M, Iakovlev VV, Scorilas A, Youssef YM, Faragalla H, Kovacs K, Rotondo F, Metias S, Arsanious A, Plotkin A, Girgis AH, Streutker CJ, Yousef GM (2012) Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis. Hum Pathol 43(7): 1037-1043.
9. Duff SE, Li C, Garland JM, Kumar S (2003) CD105 is important for angiogenesis: evidence and potential applications. FASEB J 17(9): 984-992.
10. Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H, Escudier B (2012) Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 104(2): 93-113.
11. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171(3): 1071-1076.
12. Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6(7): 655-663.
13. Gougos A, Letarte M (1990) Primary structure of endoglin, an RGDcontaining glycoprotein of human endothelial cells. J Biol Chem 265(15): 8361-8364.
14. Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, Deregibus MC, Tetta C, Bussolati B, Camussi G (2011) Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res 71(15): 5346-5356.
15. Hermann PC, Bhaskar S, Cioffi M, Heeschen C (2010) Cancer stem cells in solid tumors. Semin Cancer Biol 20(2): 77-84.
16. Kumar P, Wang JM, Bernabeu C (1996) CD 105 and angiogenesis. J Pathol 178(4): 363-366.
17. Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N, Kumar S (2000) Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 89(2): 122-126.
18. Minardi D, Lucarini G, Mazzucchelli R, Milanese G, Natali D, Galosi AB, Montironi R, Biagini G, Muzzonigro G (2005) Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens. J Urol 174(4 Pt 1): 1208-1212.
19. Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O (2006) Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers. Pathol Int 56(12): 717-723.
20. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS (2012) A phase I first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. Clin Cancer Res 18(17): 4820-4829.
21. Sandlund J, Hedberg Y, Bergh A, Grankvist K, Ljungberg B, Rasmuson T (2006) Endoglin (CD105) expression in human renal cell carcinoma. BJU Int 97(4): 706-710.
22. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M (1997) Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 3(7): 1031-1044.
23. Sudarshan S, Karam JA, Brugarolas J, Thompson RH, Uzzo R, Rini B, Margulis V, Patard JJ, Escudier B, Linehan WM (2013) Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol 63(2): 244-251.
24. Takahashi N, Haba A, Matsuno F, Seon BK (2001) Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 61(21): 7846-7854.
25. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A(14): 2474-2484.
26. Volpe A, Patard JJ (2010) Prognostic factors in renal cell carcinoma. World J Urol 28(3): 319-327.
27. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324(1): 1-8.
28. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A (2002) Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51(4): 268-275.
29. Yagasaki H, Kawata N, Takimoto Y, Nemoto N (2003) Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol 10(4): 220-227.